Perceptive Advisors LLC Ascendis Pharma A/S Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $11.4 Million - $16.8 Million	132,176 New	132,176 $16.6 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $45.4 Million - $56.3 Million	-473,475 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $68.5 Million - $84.5 Million	-639,853 Reduced 57.47%	473,475 $54.5 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $3.77 Million - $7.89 Million	60,681 Added 5.76%	1,113,328 $131 Million
Q4 2018 Feb 14, 2019	SELL	$55.16 - $69.67 $1.1 Million - $1.39 Million	-20,000 Reduced 1.86%	1,052,647 $63 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $5.27 Million - $6.65 Million	90,000 Added 9.16%	1,072,647 $71.4 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $38.3 Million - $66.9 Million	982,647 New	982,647 $64.3 Million

241

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.29B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.